Product Data Sheet

Maplirpacept

Catalog No. A64198

main product photo
Maplirpacept is a CD47 fusion protein designed to inhibit the CD47 pathway. By binding to CD47, the protein promotes phagocytosis of cancer cells, enhancing the immune response against tumors. This reagent is utilized in research focused on immuno-oncology and the modulation of immune evasion mechanisms in cancer therapy.
Chemical Information
Catalog NumA64198
M. Wt
Formula
Purity>98%
Storageat -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
CAS No.2631667-06-4
SynonymsTTI-622; PF-07901801
SMILES
Biological Activity
DescriptionMaplirpacept is a CD47 fusion protein designed to inhibit the CD47 pathway. By binding to CD47, the protein promotes phagocytosis of cancer cells, enhancing the immune response against tumors. This reagent is utilized in research focused on immuno-oncology and the modulation of immune evasion mechanisms in cancer therapy.
RETURN POLICY
Adooq’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Adooq products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Adooq Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Adooq products are stable under the recommended conditions.